The Efficacy of Camptothecin Variants on Incidental Relapsed/Refractory  Malignancies of Childhood

Defne Ay Tuncel; Ganiye Begul Kupeli

Abstract

The Efficacy of Camptothecin Variants on Incidental Relapsed/Refractory Malignancies of Childhood

Author(s): Defne Ay Tuncel* and Ganiye Begul Kupeli

In this study, we aimed to assessed the effect of camptothecin derivatives (irinotecan and topotecan) on median survival and disease-free survival and their effect on treatment responses in relapsed/refractory patients in real-life settings. In our study, we retrospectively evaluated patients under the age of 18 who were followed up in paediatric haematology clinics with the diagnosis of relapsed/refractory wilms tumour, neuroblastoma, osteosarcoma, ewing sarcoma and Medulloblasoma (MB) between 2017 and 2022. Patients who received irinotecan as salvage therapy were included in the study. A total of 71 patients from a single centre in Turkey were included in the study. All patients received at least 2 lines of treatment before relapse/refractoriness. Median overall survival times according to the response groups obtained with Campthotesin were statistically significant (p<0.001). Median overall survival times according to the permanent response groups were statistically significant (p<0.001). Median disease-free survival times according to the response groups obtained with campthotecin were statistically significant (p<0.001). Median disease-free survival times (months) according to the permanent response groups were statistically significant (p<0.001). According to the results of the multivariate Cox regression model, topotecan use (p=0.037) decreased mortality (p<0.001, -2 loglikelihood=338.33). The response obtained with PR (p=0.023) increased disease-free survival, while topotecan use (p=0.034) decreased disease-free survival (p<0.001). Response and survival analyses obtained with the effect of camptothecin derivatives on topoisomerase indicate that appropriate treatment regimens containing camptothecin derivatives can be used for these patients.

PDF

Select your language of interest to view the total content in your interested language